Quote Request
Whole-Genome Sequencing for Pancreatic Cancer
Pancreatic cancer is a challenging disease driven by genetic alterations in key cancer-associated genes. Despite slow progress in treatments over the past 30 years, deep sequencing of pancreatic cancer genomes is advancing the search for new therapeutic targets. At Alfa Cytology, we offer customizable pancreatic cancer WGS and bioinformatics analysis services through our large-scale sequencing platforms.
Overview of Pancreatic Cancer Whole-genome Sequencing (WGS)
WGS involves decoding the complete DNA sequence of an organism, capturing all genetic variations across the entire genome. For pancreatic cancer, a notoriously aggressive malignancy with high genomic complexity, WGS is a powerful tool for identifying oncogenic mutations, structural variations, and copy number changes. It plays a pivotal role in uncovering the genetic drivers of tumorigenesis and metastasis, as well as in tracking tumor evolution over time.
Fig. 1 Whole-genome sequencing (WGS) data reveal diverse forms of genomic alteration (Zhao EY, et al., 2019)
Cancer WGS using next-generation sequencing (NGS) provides base-pair level analysis of mutations specific to cancer tissue. WGS greatly facilitates the discovery of new cancer-associated variants, including single nucleotide locus variants (SNV), copy number variations, insertions/deletions (indel), and structural variants. Nowadays, WGS has been widely used in cancer research, including pancreatic cancer research. This sequencing technology has revealed many cancer-related variants, such as new cancer driver mutations. There are some advantages of cancer WGS, including,
- Cancer WGS provides the most comprehensive identification of variants, even if they are outside the coding region
- WGS can provide base-pair resolution for the entire cancer genome in a single run
- WGS can provide a comprehensive view of mutations and genomic alterations specific to cancer tissue
- WGS can provide a comprehensive understanding of the changes in tumor-specific DNA samples relative to normal DNA
Our Services
Based on advanced sequencing platforms, we actively support researchers all over the world with their pancreatic cancer genome sequencing needs. We accept not only tumor tissue samples but also pancreatic cancer cell lines. Our services include experimental design, sample preparation, sequencing, and cancer genome association analysis. We are committed to offering an unprecedented amount of deep WGS data to facilitate pancreatic cancer research. Specifically, our capabilities can help customers achieve the following goals but are not limited to:
Identification of Novel Pancreatic Cancer Susceptibility Genes
This service aims to discover new genes that increase the risk of developing pancreatic cancer. By using advanced genetic analysis techniques, we identify genetic variants in individuals with a predisposition to pancreatic cancer, helping to uncover new markers for early detection and personalized risk assessment.
Identification of Novel Pancreatic Cancer Driver Genes
This service focuses on finding new driver genes that contribute to pancreatic cancer development and progression. By analyzing tumor samples at the genomic level, we identify mutations that are key to tumor growth, providing insights into potential therapeutic targets.
Identification of New Pancreatic Cancer DNA Repair Genes
This service identifies DNA repair genes that are involved in maintaining genomic stability in pancreatic cancer cells. Understanding these genes can reveal vulnerabilities in cancer cells, which can be targeted to improve treatment outcomes or guide the development of new therapeutic strategies.
Why Choose Alfa Cytology?
- Scalable throughput, flexible sequencing
- Capable of successfully enriching samples with limited amounts of DNA
- A fast, integrated analysis workflow
- The growing database of validated genomes can provide powerful support to researchers in identifying pancreatic cancer mechanisms, drug targets, prognosis, and predictive biomarkers.
Cancer WGS helps analyze oncogenes, tumor suppressor genes, and other risk factors. At Alfa Cytology, our goal is to apply state-of-the-art infrastructure as well as market-leading technology to promote pancreatic cancer research and drug development. Our global customer base includes pharmaceutical, biotechnology, and research institutions. Whatever the size and complexity of your project, please contact us for a professional, competitively-priced solution that fits your needs.
Reference
- Zhao EY, Jones M, Jones SJM. Whole-Genome Sequencing in Cancer. Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a034579.
